Antimyostatin treatment in health and disease: The story of great expectations and limited success
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Antimyostatin treatment in health and disease : The story of great expectations and limited success. / Nielsen, Tue L.; Vissing, John; Krag, Thomas O.
I: Cells, Bind 10, Nr. 3, 533, 2021.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Antimyostatin treatment in health and disease
T2 - The story of great expectations and limited success
AU - Nielsen, Tue L.
AU - Vissing, John
AU - Krag, Thomas O.
N1 - Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021
Y1 - 2021
N2 - In the past 20 years, myostatin, a negative regulator of muscle mass, has attracted attention as a potential therapeutic target in muscular dystrophies and other conditions. Preclinical studies have shown potential for increasing muscular mass and ameliorating the pathological features of dystrophic muscle by the inhibition of myostatin in various ways. However, hardly any clinical trials have proven to translate the promising results from the animal models into patient popula-tions. We present the background for myostatin regulation, clinical and preclinical results and dis-cuss why translation from animal models to patients is difficult. Based on this, we put the clinical relevance of future antimyostatin treatment into perspective.
AB - In the past 20 years, myostatin, a negative regulator of muscle mass, has attracted attention as a potential therapeutic target in muscular dystrophies and other conditions. Preclinical studies have shown potential for increasing muscular mass and ameliorating the pathological features of dystrophic muscle by the inhibition of myostatin in various ways. However, hardly any clinical trials have proven to translate the promising results from the animal models into patient popula-tions. We present the background for myostatin regulation, clinical and preclinical results and dis-cuss why translation from animal models to patients is difficult. Based on this, we put the clinical relevance of future antimyostatin treatment into perspective.
KW - ActRIIB
KW - Muscular dystrophy
KW - Muscular regeneration
KW - Myostatin
KW - TGF-β
U2 - 10.3390/cells10030533
DO - 10.3390/cells10030533
M3 - Review
C2 - 33802348
AN - SCOPUS:85103863032
VL - 10
JO - Cells
JF - Cells
SN - 2073-4409
IS - 3
M1 - 533
ER -
ID: 303674000